ЗНАЧЕНИЕ НОВОГО БИОМАРКЕРА ST2 В РАЗВИТИИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
Ключевые слова:
острая сердечная недостаточность, прогноз, биомаркер ST2, натрийуретический пептид, PresageАннотация
В статье приводятся данные по новому биомаркеру ST2, его прогностической значимости у больных с СН. Описаны результаты крупных исследований, оценивавших его значимость в сранении с другими прогностическими маркерами.
Библиографические ссылки
Ko DT, Tu JV, Masoudi FA, Wang Y, Havranek EP, Rathore SS, Newman AM, Donovan LR, Lee DS, Foody JM, Krumholz HM. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada. Arch Intern Med 2005;165: 2486-2492.
Januzzi JL Jr, Felker GM. Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail 2013;1:213-215.
van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin Chem 2012;58:127e138.
Daniels L, M A. Natriuretic peptides. JACC 2007;50:2357e2368.
Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kB-dependent mechanism. J Clin Invest 1999;101:1603e1612.
Fonarow G, Peacock W, Phillips C, Givertz M, M L. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. JACC 2007;49:1943-1950.
Chen A, Wood M, Krauser D, Baggish A, Tung R, Anwaruddin S, Picard M, JL J. NT-proBNP levels, echocardiographic findings, and 30B The American Journal of Cardiology (www.AJConline.org) Vol 115 (7S) April 2, 2015 outcomes in breathless patients: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006;27:839e845.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147ee239.
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721e726.
Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106: 2961-2966.
Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-691.
Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50: 607-613.
Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;S4:752-756.
Rehman S, Mueller T, JL J. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. JACC 2008;52:1458-1465.
Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-267.
Shah R, Chen-Tournoux A, Picard M, van Kimmenade R, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009;2:311-319.
Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high sensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta 2009;409:33-40.
Mueller T, Dieplinger B. The Presage ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2012;13:13-30.
Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. Clin Chim Acta 2012;413: 1493-1494.
Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi JL Jr. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012;16:R135.
Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Penalver M, Andreu-Cayuelas JM, Valdes M. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012;122:158-166.
Januzzi JL Jr, van Kimmenade RR. Importance of rigorous evaluation in comparative biomarker studies. J Am Coll Cardiol 2013;63: 167-169.
Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168: 2186-2194
